Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naive Subjects with Acute Myeloid Leukemia who are Ineligible for Standard Induction Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myeloproliferative disorders
- Focus Registrational; Therapeutic Use
- Acronyms VIALE-A
- Sponsors AbbVie; AbbVie Germany; Roche
- 12 Dec 2023 Results of pooled analysis, evaluating the outcomes of Ven+Aza across elderly age cohorts in patients with ND AML from NCT02203773 and Ven+Aza versus Pbo+Aza in patients with ND AML who were IC-ineligible from NCT02993523, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 27 Jun 2023 Planned End Date changed from 25 Sep 2023 to 25 Sep 2024.
- 15 Jun 2023 Results assessing long-term outcomes with health-related quality of life in patients with acute myeloid leukemia presented at the 28th Congress of the European Haematology Association